Phase II brain metastases trial advances after futility analysis
The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study. The trial is being run by NH TherAguix, a biotechnology company developing… Read More